Omega Therapeutics

What Omega Therapeutics does

Omega Therapeutics was a Cambridge, Massachusetts-based, publicly traded clinical-stage biotechnology company (NASDAQ: OMGA) founded in 2016 that developed programmable epigenetic medicines. The company built its business around a proprietary platform called the Omega Platform, which uses mRNA-based Epigenetic Modular Effectors (OMERs) to control gene expression in a reversible manner without altering DNA. This mechanism was positioned as differentiated from CRISPR-based permanent gene editing and from conventional mRNA vaccines.

The company's pipeline included lead candidate OTX-2002 in Phase 1/2 development for hepatocellular carcinoma, OTX-TKI for solid tumors, and additional rare genetic disease programs that received FDA Orphan Drug and Breakthrough Therapy designations. Target therapeutic areas spanned oncology, regenerative medicine, and rare genetic diseases. Omega Therapeutics had no commercial products, no disclosed pricing, and no distribution channels; its business model was research and clinical development funded by equity capital rather than product revenue.

The company raised approximately $279.4 million in cumulative equity financing across venture and post-IPO rounds, with Flagship Pioneering as the founding and lead investor across multiple rounds and broad institutional participation in the 2021 Series C. Despite clinical progression and regulatory designations, the company shut down operations in 2025 amid challenging biotech market conditions, high development costs, and difficulty raising additional capital.

Name

Omega Therapeutics

Website

https://omegatherapeutics.com

Company type

Public

Founded year

2016

Operating status

Closed

Headcount range

51–100 employees

Short description

Omega Therapeutics was a Cambridge-based clinical-stage biotechnology company that developed programmable epigenetic mRNA medicines using its proprietary Omega Platform and OMERs technology to treat oncology and rare genetic disease patients; the company ceased operations in 2025.

Ownership category

akta.pro rank

Product category

Epigenetic Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• Epigenomic medicines
• Programmable epigenetics
• MRNA therapeutics
• Gene expression control
• Oncology therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

Omega Therapeutics developed programmable epigenomic mRNA medicines using its proprietary Omega Platform and OMERs technology to enable reversible control of gene expression without altering DNA. Its pipeline focused on therapeutic candidates for hepatocellular carcinoma (OTX-2002), solid tumors (OTX-TKI), regenerative medicine, and rare genetic diseases.

Product overview

Omega Therapeutics developed a single unified platform architecture centered on its proprietary Omega Platform and OMERs technology, which enables programmable epigenome editing without permanent DNA alteration. The company's therapeutic portfolio included lead candidate OTX-2002 for hepatocellular carcinoma and OTX-TKI for solid tumors, all leveraging the same core platform technology to target oncology, regenerative medicine, and rare genetic diseases. Note: The company shut down in 2025 according to multiple sources.

Differentiator

Problem solved

Functional benefit

Products and services

• Omega Platform
• OMERs Technology (Omega Epigenetic Regulators)
• OTX-2002
• OTX-TKI

Quantifiable outcome

• Phase 1/2 clinical trials for OTX-2002 in hepatocellular carcinoma
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Beam Therapeutics: Beam Therapeutics is a broad incumbent in base editing, offering precision gene editing capabilities across oncology and rare disease indications overlapping with Omega's target segments.
• Editas Medicine: Editas Medicine is a broad incumbent in CRISPR-based gene editing and cell therapies, with clinical programs in oncology and rare genetic diseases that compete for the same therapeutic indications as Omega.
• Sangamo Therapeutics: Sangamo is a broad incumbent in genomic medicine with zinc finger nuclease-based gene regulation capabilities, operating across multiple disease areas with overlapping gene modulation applications.
• Intellia Therapeutics: Intellia is a broad incumbent in CRISPR/Cas9-based gene editing with clinical-stage assets across multiple indications, representing the dominant gene editing modality Omega's platform was differentiated against.

Emerging players

• Tessera Therapeutics: Tessera Therapeutics is an emerging player in gene writing technology, pursuing programmable genomic modifications that overlap conceptually with Omega's approach to controlling gene expression.
• Arcturus Therapeutics: Arcturus Therapeutics is an emerging player in mRNA therapeutics technology, sharing Omega's mRNA-based delivery modality but focused primarily on vaccines and protein replacement rather than epigenome editing.
• Prime Medicine: Prime Medicine is an emerging player in prime editing technology, offering a different precision gene editing modality that targets similar disease areas and competes for partnership and capital attention in the gene medicine space.

Direct peers

• Tune Therapeutics: Tune Therapeutics is a direct peer focused on epigenetic gene silencing and reprogramming, employing programmable approaches that closely mirror Omega's reversible epigenome editing strategy.
• Chroma Medicine: Chroma Medicine is a direct peer developing epigenetic editing therapeutics using a similar programmable approach to gene regulation without altering DNA sequence, directly competing in the same modality as Omega's OMERs platform.

Others

• Epicypher: Epicypher is an adjacent tools and reagents provider for chromatin and epigenomics research, supplying enabling technologies that support epigenome editing platforms including Omega's drug discovery efforts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/omegatx
• LinkedInlinkedin.com/company/omega-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omega Therapeutics